A Phase 1 interventional study of BMS-663068 and Maraviroc in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-25.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the active moiety of BMS-663068), there is no formal hypothesis to be statistically tested. The purpose of this assessment is to estimate the effect of maraviroc on the PK of BMS-626529 when coadministered in healthy subjects. For the effect of BMS-663068 on the PK of maraviroc, the hypothesis to be statistically tested is that BMS-663068 will not have a clinically significant effect on the PK of maraviroc when coadministered in healthy subjects.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 112 is close to the median of 113 across 1,304 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A: BMS-663068 orally twice daily (BID) on Days 1 through 4 Treatment B: Maraviroc BID on Days 7 through 11 Treatment C: BMS-663068 BID plus maraviroc BID on Days 12 through 18
Drug: BMS-663068 · Drug: Maraviroc
BMS-663068
Maraviroc
BMS-626529 Pharmacokinetics: maximum observed plasma concentration (Cmax)
PK parameters for BMS-626529 in the absence or presence of multiple doses of maraviroc include: - Cmax
Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18
BMS-626529 Pharmacokinetics: area under the plasma concentration-time curve (AUC) in a single dosing interval AUC(TAU)
PK parameters for BMS-626529 in the absence or presence of multiple doses of maraviroc include: - AUC(TAU)
Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18
Maraviroc Pharmacokinetics: Cmax
PK parameters for maraviroc in the absence or presence of BMS-663068 include: - Cmax
Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18
Maraviroc Pharmacokinetics: AUC(TAU)
PK parameters for maraviroc in the absence or presence of BMS-663068 include: - AUC(TAU)
Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18
Other PK Parameters for BMS-626529: Time of maximum observed plasma concentration (Tmax)
PK parameters for BMS-626529 include: - Tmax
Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18
Other PK Parameters for BMS-626529: plasma concentration observed at 12 hours post-dose (C12)
PK parameters for BMS-626529 include: - C12
Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18
Other PK Parameters for BMS-626529: trough observed plasma concentration (Ctrough) (predose)
PK parameters for BMS-626529 include: - Ctrough (predose)
Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18
Other PK Parameters for maraviroc: Tmax
PK Parameters for maraviroc include: -Tmax
Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18
Other PK Parameters for maraviroc: C12
PK Parameters for maraviroc include: * C12
Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18
Other PK Parameters for maraviroc: Ctrough
PK Parameters for maraviroc include: - Ctrough
Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18
Clinical Safety as Measured by Adverse Events
Adverse event monitoring
Time frame: Day 1 to Day 26
Clinical Safety as Measured by Vital Signs
Vital sign measurement
Time frame: Day 1 to Day 26
Clinical Safety as Measured by Electrocardiograms (ECGs)
12-lead ECGs
Time frame: Day 1 to Day 26
Clinical Safety as Measured by Physical Examination
Physical examinations
Time frame: Day 1 to Day 26
Clinical Safety as Measured by Clinical Laboratory Evaluations
Clinical chemistry, hematology, urinalysis
Time frame: Day 1 to Day 26
Ran from Jul 2015 to primary completion in Sep 2015, 2 months.
Of 51 industry-sponsored phase 1 interventional studies under Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 2 months is below that.
Counting every sponsor, half of 78 studies reached it within 10 months; a quarter within 3 and three quarters within 20.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fostemsavir · Maraviroc